<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35019862</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3008</ISSN><JournalIssue CitedMedium="Internet"><Volume>50</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Exercise and sport sciences reviews</Title><ISOAbbreviation>Exerc Sport Sci Rev</ISOAbbreviation></Journal><ArticleTitle>Exercise as a Moderator of Persistent Neuroendocrine Symptoms of COVID-19.</ArticleTitle><Pagination><StartPage>65</StartPage><EndPage>72</EndPage><MedlinePgn>65-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1249/JES.0000000000000284</ELocationID><Abstract><AbstractText>Precipitated by chronic psychological stress, immune system dysregulation, and a hyperinflammatory state, the sequelae of postacute COVID-19 (long COVID) include depression and new-onset diabetes. We hypothesize that exercise counters the neuropsychiatric and endocrine sequelae of long COVID by inducing the release of circulating factors that mediate the anti-inflammatory response, support brain homeostasis, and increase insulin sensitivity.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the American College of Sports Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rebello</LastName><ForeName>Candida J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, LA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Axelrod</LastName><ForeName>Christopher L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, LA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Charles F</ForeName><Initials>CF</Initials><Suffix>3rd</Suffix><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine, Pittsburg, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenway</LastName><ForeName>Frank L</ForeName><Initials>FL</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, LA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>John P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Pennington Biomedical Research Center, Baton Rouge, LA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K99 AG065419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R00 AG065419</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM104940</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Exerc Sport Sci Rev</MedlineTA><NlmUniqueID>0375434</NlmUniqueID><ISSNLinking>0091-6331</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015444" MajorTopicYN="N">Exercise</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>12</Day><Hour>12</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35019862</ArticleId><ArticleId IdType="mid">NIHMS1767127</ArticleId><ArticleId IdType="pmc">PMC8900884</ArticleId><ArticleId IdType="doi">10.1249/JES.0000000000000284</ArticleId><ArticleId IdType="pii">00003677-202204000-00002</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A Sehgal K Gupta A, et al. . Post-acute COVID-19 syndrome. Nat. Med. 2021; 27(4):601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM Mateus J Kato Y, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021; 371(6529):eabf4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C Wang Z Lorenzi JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021; 591(7851):639&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JK, Lin SS, Ji XJ, Guo LM. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol. 2010; 47(3):193&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088164</ArticleId><ArticleId IdType="pubmed">19333547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CT Lidsky PV Xiao Y, et al. . SARS-CoV-2 infects human pancreatic &#x3b2; cells and elicits &#x3b2; cell impairment. Cell Metab. 2021; 33(8):1565&#x2013;76.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8130512</ArticleId><ArticleId IdType="pubmed">34081912</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallis R Young DR Tartof SY, et al. . Physical inactivity is associated with a higher risk for severe COVID-19 outcomes: a study in 48 440 adult patients. Br. J. Sports Med. 2021; 55:1099&#x2013;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">33849909</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 2000; 21(1):55&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">10696570</ArticleId></ArticleIdList></Reference><Reference><Citation>Golden SH Lazo M Carnethon M, et al. . Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008; 299(23):2751&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2648841</ArticleId><ArticleId IdType="pubmed">18560002</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001; 24(6):1069&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">11375373</ArticleId></ArticleIdList></Reference><Reference><Citation>Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BM, Colao A. Complications of Cushing's syndrome: state of the art. Lancet Diabetes Endocrinol. 2016; 4(7):611&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">27177728</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustman PJ Griffith LS Clouse RE, et al. . Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial. Psychosom. Med. 1997; 59(3):241&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">9178335</ArticleId></ArticleIdList></Reference><Reference><Citation>Katon WJ Von Korff M Lin EH, et al. . The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch. Gen. Psychiatry. 2004; 61(10):1042&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15466678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha DS Best MW Bowie CR, et al. . A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorder. J. Affect. Disord. 2017; 210:57&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">28013123</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M Mi J Jiang QM, et al. . Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus. Clin. Exp. Pharmacol. Physiol. 2014; 41(9):650&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24862430</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann RT Edelstein SL Narayan KM, et al. . Changes in health state utilities with changes in body mass in the diabetes prevention program. Obesity (Silver Spring). 2009; 17(12):2176&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3135001</ArticleId><ArticleId IdType="pubmed">19390518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gujral S, Aizenstein H, Reynolds CF, 3rd, Butters MA, Erickson KI. Exercise effects on depression: possible neural mechanisms. Gen. Hosp. Psychiatry. 2017; 49:2&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437683</ArticleId><ArticleId IdType="pubmed">29122145</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve. Clin. J. Med. 2017; 84(7 Suppl. 1):S15&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5846677</ArticleId><ArticleId IdType="pubmed">28708479</ArticleId></ArticleIdList></Reference><Reference><Citation>Traustadottir T, Bosch PR, Matt KS. The HPA axis response to stress in women: effects of aging and fitness. Psychoneuroendocrinology. 2005; 30(4):392&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pubmed">15694119</ArticleId></ArticleIdList></Reference><Reference><Citation>Babyak M Blumenthal JA Herman S, et al. . Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychosom. Med. 2000; 62(5):633&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">11020092</ArticleId></ArticleIdList></Reference><Reference><Citation>Lysy Z, Da Costa D, Dasgupta K. The association of physical activity and depression in type 2 diabetes. Diabet. Med. 2008; 25(10):1133&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19046190</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinger I, Selig S, Goodman C, Jerums G, Stewart A, Hare DL. Resistance training improves depressive symptoms in individuals at high risk for type 2 diabetes. J. Strength Cond. Res. 2011; 25(8):2328&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">21659891</ArticleId></ArticleIdList></Reference><Reference><Citation>Piette JD Richardson C Himle J, et al. . A randomized trial of telephonic counseling plus walking for depressed diabetes patients. Med. Care. 2011; 49(7):641&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3117978</ArticleId><ArticleId IdType="pubmed">21478777</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot M Doyle T Kushnick M, et al. . Can lifestyle interventions do more than reduce diabetes risk? Treating depression in adults with type 2 diabetes with exercise and cognitive behavioral therapy. Curr. Diab. Rep. 2012; 12(2):157&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3314326</ArticleId><ArticleId IdType="pubmed">22350739</ArticleId></ArticleIdList></Reference><Reference><Citation>de Groot M Shubrook JH Hornsby WG Jr., et al. . Program ACTIVE II: outcomes from a randomized, multistate community-based depression treatment for rural and urban adults with type 2 diabetes. Diabetes Care. 2019; 42(7):1185&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6609961</ArticleId><ArticleId IdType="pubmed">31221693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yates T, Gray LJ, Henson J, Edwardson CL, Khunti K, Davies MJ. Impact of depression and anxiety on change to physical activity following a pragmatic diabetes prevention program within primary care: pooled analysis from two randomized controlled trials. Diabetes Care. 2019; 42(10):1847&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">31399440</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvam S, Kleppe CL, Nordhus IH, Hovland A. Exercise as a treatment for depression: a meta-analysis. J. Affect. Disord. 2016; 202:67&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">27253219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X Zhang X Guo J, et al. . Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc. 2015; 4(7):e002014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4608087</ArticleId><ArticleId IdType="pubmed">26116691</ArticleId></ArticleIdList></Reference><Reference><Citation>Donath MY, Dinarello CA, Mandrup-Poulsen T. Targeting innate immune mediators in type 1 and type 2 diabetes. Nat. Rev. Immunol. 2019; 19(12):734&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rui L Aguirre V Kim JK, et al. . Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways. J. Clin. Invest. 2001; 107(2):181&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC199174</ArticleId><ArticleId IdType="pubmed">11160134</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1&#x2013;mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha&#x2013; and obesity-induced insulin resistance. Science. 1996; 271(5249):665&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8571133</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ Higashimori T Park SY, et al. . Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53(4):1060&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15047622</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen CM Faulenbach M Vaag A, et al. . Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 2007; 356(15):1517&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">17429083</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma S, Mathew V, Farkouh ME. Targeting inflammation in the prevention and treatment of type 2 diabetes: insights from CANTOS. J. Am. Coll. Cardiol. 2018; 71(21):2402&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">29793628</ArticleId></ArticleIdList></Reference><Reference><Citation>Steensberg A, Fischer CP, Keller C, Moller K, Pedersen BK. IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. Am. J. Physiol. Endocrinol. Metab. 2003; 285(2):E433&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12857678</ArticleId></ArticleIdList></Reference><Reference><Citation>del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am. J. Phys. 1999; 276(5):E849&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">10329978</ArticleId></ArticleIdList></Reference><Reference><Citation>Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003; 17(8):884&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12626436</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellingsgaard H Hauselmann I Schuler B, et al. . Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011; 17(11):1481&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286294</ArticleId><ArticleId IdType="pubmed">22037645</ArticleId></ArticleIdList></Reference><Reference><Citation>Mooney RA. Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 2007; 102(2):816&#x2013;8; discussion 8-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17284655</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc. Immunol. Rev. 2006; 12:6&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">17201070</ArticleId></ArticleIdList></Reference><Reference><Citation>Spranger J Kroke A Mohlig M, et al. . Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003; 52(3):812&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12606524</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid&#x2013;induced insulin resistance. J. Clin. Invest. 2006; 116(11):3015&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1616196</ArticleId><ArticleId IdType="pubmed">17053832</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarlin BK Flynn MG Campbell WW, et al. . Physical activity status, but not age, influences inflammatory biomarkers and toll-like receptor 4. J. Gerontol. A Biol. Sci. Med. Sci. 2006; 61(4):388&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611706</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart LK Flynn MG Campbell WW, et al. . Influence of exercise training and age on CD14+ cell-surface expression of toll-like receptor 2 and 4. Brain Behav. Immun. 2005; 19(5):389&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">15963685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sriwijitkamol A Christ-Roberts C Berria R, et al. . Reduced skeletal muscle inhibitor of kappaB beta content is associated with insulin resistance in subjects with type 2 diabetes: reversal by exercise training. Diabetes. 2006; 55(3):760&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16505240</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan JP, Jing M. Modulation of insulin signaling in human skeletal muscle in response to exercise. Exerc. Sport Sci. Rev. 2002; 30(2):85&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">11991543</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer HF, Goodyear LJ. Exercise, MAPK, and NF-kappaB signaling in skeletal muscle. J. Appl. Physiol. (1985). 2007; 103(1):388&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">17303713</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson RJ, Kunz H, Agha N, Graff R. Exercise and the regulation of immune functions. Prog. Mol. Biol. Transl. Sci. 2015; 135:355&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">26477922</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenze EJ Mattar C Zorumski CF, et al. . Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial. JAMA. 2020; 324(22):2292&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7662481</ArticleId><ArticleId IdType="pubmed">33180097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur. J. Pharmacol. 2014; 727:167&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24508523</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121):860&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17167474</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller JA Gross R Conzelmann C, et al. . SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat. Metab. 2021; 3(2):149&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">33536639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirwan JP, Solomon TP, Wojta DM, Staten MA, Holloszy JO. Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am. J. Physiol. Endocrinol. Metab. 2009; 297(1):E151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2711659</ArticleId><ArticleId IdType="pubmed">19383872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L She ZG Cheng X, et al. . Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31(6):1068&#x2013;77.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252168</ArticleId><ArticleId IdType="pubmed">32369736</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwingshackl L, Missbach B, Dias S, Konig J, Hoffmann G. Impact of different training modalities on glycaemic control and blood lipids in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetologia. 2014; 57(9):1789&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">24996616</ArticleId></ArticleIdList></Reference><Reference><Citation>Grace A, Chan E, Giallauria F, Graham PL, Smart NA. Clinical outcomes and glycaemic responses to different aerobic exercise training intensities in type II diabetes: a systematic review and meta-analysis. Cardiovasc. Diabetol. 2017; 16(1):37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5351065</ArticleId><ArticleId IdType="pubmed">28292300</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Sports Medicine . ACSM's Guidelines for Exercise Testing and Prescription. 11th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2022. 548 p.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>